期刊文献+

肿瘤药物基因组学研究进展 被引量:7

Study advance in tumor pharmacogenomics
暂未订购
导出
摘要 药物基因组学对于解释药物反应的个体差异及开展个体化用药具有重要意义。近年来药物基因组学新技术在肿瘤药物治疗方面的进展和应用鉴定出多种影响肿瘤药物治疗的遗传变异,深刻影响肿瘤治疗的药物研发及个体化治疗。本文通过举例说明近期肿瘤药物基因组学重要研究进展的临床应用评价及面临的挑战,对肿瘤药物基因组学的发展及其临床应用进行综述。 Pharmacogenetics is essential for explanation on individual variation of drug responses, and application of personalized medicine. Recently new technology and developments of pharmacokinetics have identified several important genetic variations involving in anticancer medication, which impact on drug development as well as individualized treatment of tumor therapy. This article aims to review the genetic factor in medication, and advancements in tumor pharmacogenomics, as well as the clinical application and challenge of advancements on tumor therapy, so as to improve research, clinical application and personalized medicine of cancer therapy.
作者 刘昭前
出处 《肿瘤药学》 CAS 2011年第2期82-89,共8页 Anti-Tumor Pharmacy
基金 国家自然科学基金项目(NO:30873089) 教育部"长江学者"创新团队(IRT-0946) 湖南省高校科技创新团队支持计划 湖南省高校创新平台开放基金(10K078) 湖南省科技计划重点项目(2009TP4068-2)
关键词 药物基因组学 肿瘤治疗 药代动力学 药效动力学 毒性反应 pharmacogenomics cancer therapy pharmacokinetics pharmacodynamics toxic reaction
  • 相关文献

参考文献1

二级参考文献10

  • 1National Cancer Institute.Common Terminology Criteria for Adverse Events V3.0. http://ctep.cancer.gov/protocol Development/electronic_applications/docs/ctcaev3.pdf .
  • 2Rouits E,Charasson V,Pétain A,et al.Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer pa-tients[].British Journal of Cancer.2008
  • 3Chabot,GG.Clinical pharmacokinetics of irinotecan[].Clinical Pharmacokinetics.1997
  • 4F Innocenti,SD Undevia,L Iyer,PX Chen,S Das,M Kocherginsky,T Karrison,L Janisch,J Ramirez,CM Rudin,EE Vokes,MJ Ratain.Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan[].Clinical Oncology.2004
  • 5Ando Y,Saka H,Ando M,et al.Polymorphisms of UDPglucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis[].Cancer Research.2000
  • 6Massacesi C,Terrazzino S,Marcucci F,et al.Uridine diphos-phate glucuronosyl transferase 1A1 promoter polymorphism pre-dicts the risk of gastrointestinal toxicity and fatigue induced by iri-notecan-based chemotherapy[].Cancer.2006
  • 7Yong WP,Innocenti F,Ratain MJ.The role of pharmacogenetics in cancer therapeutics[].British Journal of Clinical Pharmacology.2006
  • 8Hall D,G Ybazeta,G Destro-Bisol,et al.Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates[].Pharmacogenetics.1999
  • 9Premawardhena,A,Fisher,CA,Liu,YT,Verma,IC,de,Silva,S,Arambepola,M.The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications[].Blood Cells Mol Diseases.2003
  • 10Zhang A,,Xing Q,Qin S,et al.Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase1A1gene in Chinese populations[].Pharmacogenomics.2007

共引文献18

同被引文献95

引证文献7

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部